Episode 367: Abiraterone vs AR Inhibitors (Fanta vs Coke) in Prostate Cancer

Chuck Ryan, MD, of Memorial Sloan Kettering Cancer Center, joins the podcast to discuss various aspects of AR inhibition in prostate cancer and the treatment’s relative benefits and risks.

While previous discussion on AR inhibitors and ARPIs has been dubbed a “Coke versus Pepsi” debate, Brian considers this new discussion comparing abiraterone with AR inhibitors as a “Fanta versus Coke” situation.